BLCO
Bausch + Lomb Corp.

522
Mkt Cap
$6.07B
Volume
230,589.00
52W High
$17.86
52W Low
$10.45
PE Ratio
-19.85
BLCO Fundamentals
Price
$17.03
Prev Close
$17.15
Open
$17.16
50D MA
$16.95
Beta
1.11
Avg. Volume
339,222.35
EPS (Annual)
-$0.9011
P/B
0.94
Rev/Employee
$354,888.89
$11,044.51
Loading...
Loading...
News
all
press releases
BLCO or DHR: Which Is the Better Value Stock Right Now?
BLCO vs. DHR: Which Stock Is the Better Value Option?
Zacks·2d ago
News Placeholder
More News
News Placeholder
Bausch + Lomb Corporation (NYSE:BLCO) Given Average Rating of "Hold" by Brokerages
Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen ratings firms that are covering the firm, Marketbeat Ratings reports. Two...
MarketBeat·3d ago
News Placeholder
Bausch + Lomb (NYSE:BLCO) Trading Down 0.9% - Here's Why
Bausch + Lomb (NYSE:BLCO) Stock Price Down 0.9% - Time to Sell...
MarketBeat·6d ago
News Placeholder
Bausch + Lomb (NYSE:BLCO) Shares Down 0.9% - What's Next?
Bausch + Lomb (NYSE:BLCO) Stock Price Down 0.9% - Should You Sell...
MarketBeat·6d ago
News Placeholder
BLCO vs. HQY: Which Stock Is the Better Value Option?
BLCO vs. HQY: Which Stock Is the Better Value Option?
Zacks·19d ago
News Placeholder
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial...
Business Wire·23d ago
News Placeholder
Bausch + Lomb Corporation (NYSE:BLCO) Receives Consensus Recommendation of "Hold" from Analysts
Shares of Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) have been given a consensus recommendation of "Hold" by the fifteen brokerages that are presently covering the company...
MarketBeat·28d ago
News Placeholder
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with...
Business Wire·1mo ago
News Placeholder
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (Bausch + Lomb or the company), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed...
Business Wire·1mo ago
News Placeholder
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive...
Business Wire·2mo ago
<
1
2
...
>

Latest BLCO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.